☰

Sarcura GmbH

Data integrity for cell therapy scale-up

A cell therapy manufacturer scaling its SiPlex silicon microfluidic platform with GxP data integrity and modular integration

Industry
Cell Therapy Manufacturing (Silicon-Based Microfluidic Medical Devices)
Headquarters
Graz, Austria
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Sarcura GmbH's published strategy and is not endorsed by, or produced in cooperation with, Sarcura GmbH. Company website

Strategic priorities

Sarcura GmbH is an Austrian deep-tech company miniaturizing cell therapy manufacturing from room-sized cleanrooms to silicon chip-based microfluidic systems. The SiPlex platform integrates CMOS-compatible silicon photonics with multiplexed microfluidic sorting to process 20 million cells per minute on a single chip — a 100x throughput improvement over conventional cleanroom-based manufacturing. The company is executing a strategic transition from proof-of-concept with imec to scalable commercial production, targeting hospital-based decentralized manufacturing that eliminates the logistics and cryopreservation costs limiting patient access to CAR-T therapies.

The immediate challenge is building the software infrastructure to match the hardware ambition. Decentralized hospital-based manufacturing requires every device to meet identical GMP quality standards, but the current reliance on manual data entry and paper-based workflows creates significant ALCOA+ compliance risks. The SiPlex platform must achieve plug-and-produce interoperability with existing hospital and laboratory infrastructure through standards like MTP and OPC UA — a challenge compounded by the 57% of labs that cite lack of knowledge as a digitalization barrier. Connected autonomous devices handling sensitive patient genetic data also introduce cybersecurity vulnerabilities that NIS2 and IEC 62443 compliance demand are systematically addressed.

The longer-term challenge is the capital-intensive transition from prototype to commercial scale. The EUR 20 million required for the next development phase arrives in a 2024-2025 funding environment where growth capital for hardware-intensive deep-tech has contracted sharply. The complexity of integrating silicon photonics with microfluidics and MEMS on CMOS-compatible substrates — while maintaining sterility and cell viability — extends development timelines beyond typical venture funding horizons.

Challenges we see

  • Operations Financing

    Financing the transition from prototype to scalable commercial production

    The SiPlex platform required massive capital investment to move from prototype to scalable commercial production, with an estimated EUR 20 million needed for the next development phase. The 2024-2025 funding environment has seen sharp drops in growth capital for hardware-intensive deep-tech companies.

    Where the funding environment constrains capital access, the development roadmap is shortened unless alternative structures — strategic partnerships, non-dilutive funding, co-development agreements — are secured to extend the runway.

  • Compliance Regulatory

    Maintaining GxP compliance as manufacturing decentralizes to hospital sites

    Manufacturing medical products requires strict GMP adherence, and ensuring every decentralized hospital device maintains identical quality standards presents a validation challenge. Manual data entry and data islands create significant audit risks under ALCOA+ principles.

    Where GxP compliance depends on manual processes at each hospital site, the quality standard is set by the weakest site rather than by the platform specification. An automated data integrity platform means the ALCOA+ standard is enforced by the system, not by the operator.

  • Digital Integration

    Achieving plug-and-produce interoperability with legacy hospital infrastructure

    The SiPlex platform must be interoperable with existing hospital and laboratory infrastructure through MTP and OPC UA standards. 57% of labs cite lack of knowledge as the primary digitalization barrier, and the absence of standardized interfaces between silicon photonics hardware and legacy clinical systems creates integration friction.

    Where interoperability depends on custom integration work at each hospital site, the deployment timeline and cost are unknowable until the site survey is complete. MTP-compliant modular architecture means the integration is a configuration exercise, not a construction project.

  • Digital Security

    Securing connected autonomous devices against cyberattacks in hospital networks

    Connected, autonomous cell therapy manufacturing devices handle sensitive patient genetic data within hospital networks, making them targets for cyberattacks. Without Zero Trust architecture and IEC 62443 compliance, decentralized devices risk lateral movement attacks that could compromise patient data or sabotage production.

    Where cybersecurity is addressed after deployment rather than designed into the architecture, the attack surface includes every hospital network the device connects to. A zero-trust OT security framework means the device is secure by design, not by remediation.

  • Operations Manufacturing

    Engineering the semiconductor-biology interface at commercial scale

    Integrating silicon photonics with microfluidics and MEMS for delicate human immune cell handling requires cross-disciplinary expertise rarely found in either biotech or semiconductor industries. The complexity of monolithic integration on CMOS-compatible substrates while maintaining sterility and cell viability extends development timelines.

    Where cross-disciplinary expertise is assembled ad hoc for each integration challenge, the development timeline is set by the steepest learning curve, not by the product specification. Structured cross-disciplinary programme management means the learning curve is deliberately flattened.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Real-time on-chip analytics and digital twin for cell manufacturing

    Traditional cell therapy manufacturing relies on post-process quality control with data latency of days, preventing real-time course corrections and leading to batch failures that cannot be remediated before the batch is complete.

    Implement continuous on-chip analytics with digital twin capabilities that enable predictive process control and automated parameter adjustment to compensate for patient-derived cell variability, moving quality control from detective to preventive.

    • Sarcura/imec collaboration documentation, 2024

  2. MTP-compliant modular architecture for plug-and-produce integration

    Cell therapy equipment operates as isolated silos with proprietary interfaces, requiring custom spaghetti code for each integration and preventing rapid facility reconfiguration at hospital sites with limited technical support capacity.

    Deploy MTP-compliant modular architecture that enables plug-and-produce capability, allowing cell processing modules to be orchestrated within larger Facility of the Future ecosystems without bespoke integration work at each site.

    • A4BEE industry research, 2024

  3. GxP-compliant automated data integrity platform

    Manual data entry and paper-based workflows create high risks of transcription errors and ALCOA+ compliance violations during GMP audits, particularly at decentralized hospital sites with varying digital maturity.

    Automate the entire data chain from sensor to final report with tamper-proof, real-time logs that ensure complete ALCOA+ compliance and eliminate manual entry errors across all decentralized manufacturing units.

    • Sarcura technical documentation, 2024

  4. Zero-trust OT cybersecurity framework for hospital-connected devices

    Connected autonomous cell therapy devices handling patient genetic data are exposed to cyberattacks within hospital networks that were not designed with manufacturing OT security in mind, creating IEC 62443 compliance gaps.

    Implement Zero Trust security architecture with IEC 62443 compliance for all connected manufacturing devices, preventing lateral movement attacks and protecting patient genetic data and production integrity.

    • IEC 62443 standards for industrial automation, 2024

  5. Cloud-based fleet management for distributed manufacturing units

    Decentralized manufacturing across multiple hospital sites creates challenges for maintaining software updates, monitoring performance and providing technical support without dedicated on-site engineers at every location.

    Build cloud-based fleet management infrastructure enabling remote monitoring, predictive maintenance, and coordinated software deployment across all distributed SiPlex manufacturing units from a single operations centre.

    • Sarcura strategic vision documentation, 2024

What we'd propose

  • Digital Lab

    Digital twin platform for SiPlex cell manufacturing operations

    We deploy a comprehensive digital twin environment for the SiPlex platform that models cell processing operations in real time, enabling predictive analytics, virtual batch simulation before physical execution, and automated parameter adjustment that compensates for patient-derived cell variability.

    • Real-time process simulation engine

      Virtual batches running alongside physical batches

      Build a real-time simulation engine that runs virtual batch models in parallel with physical SiPlex operations, alerting operators when the active batch trajectory diverges from the optimal envelope before the divergence becomes an out-of-spec event.

    • Predictive quality control with on-chip analytics

      Quality decisions made in real time, not after the fact

      Integrate continuous on-chip analytics — flow cytometry, cell counting, viability sensing — with the digital twin model to enable predictive quality control that adjusts process parameters before the batch outcome is determined.

    • Patient-derived variability modelling

      Learning from every patient's cells to improve the next batch

      Develop patient-specific variability models that use the real-time analytics data to adapt the process parameters for each patient's cells, progressively improving the digital twin's accuracy with every campaign.

    • Batch failures detected and corrected in real time, before the batch is committed, reducing costly failed campaigns.
    • Digital twin accuracy improves with every campaign, progressively reducing the variability window for each patient population.
    • Regulatory submissions strengthened by complete in silico batch history that predates the physical batch records.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    MTP-compliant modular orchestration layer for SiPlex

    We implement an MTP-compliant modular orchestration system for the SiPlex platform, enabling plug-and-produce integration with hospital laboratory infrastructure, reconfigurable module orchestration, and standardised equipment driver management that eliminates custom spaghetti-code integration at each deployment site.

    • Module Type Package library for SiPlex

      Every module type documented and interoperable

      Develop MTP-compliant module type packages for all SiPlex processing modules — cell selection, sorting, activation, expansion — with standardised state machines, alarm handling and data exchange formats that conform to the MTP standard.

    • Plug-and-produce orchestration engine

      New modules recognised and commissioned automatically

      Build an orchestration engine that detects newly connected MTP-compliant modules, validates their type packages and commission state, and integrates them into the active production workflow without manual reconfiguration.

    • Legacy equipment adapter layer

      Existing hospital equipment integrated without custom code

      Deploy an adapter layer that wraps legacy hospital laboratory equipment — centrifuges, incubators, biosafety cabinets — with MTP-compliant interfaces, enabling them to participate in SiPlex workflows alongside native modules.

    • Site deployment timeline reduced from months to weeks by replacing custom integration with configuration.
    • Reconfigurable module orchestration enables the SiPlex to adapt to different cell therapy protocols without hardware changes.
    • Standardised MTP compliance accelerates regulatory review by demonstrating conformance to established interoperability standards.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    GxP-compliant automated data integrity platform

    We deploy an automated data management system for the SiPlex platform that ensures complete ALCOA+ compliance through automated capture, contextualisation and audit trail generation from all sensors and instruments through to the regulatory submission package.

    • Sensor-to-report automated data pipeline

      Every data point captured, timestamped and contextualised

      Build automated data pipelines from every SiPlex sensor and connected instrument that capture, normalise and contextualise data in real time, eliminating manual transcription and creating a complete, attributable data chain.

    • Tamper-proof audit trail and electronic batch record

      Audit-ready records that cannot be retrospectively altered

      Implement an electronic batch record system with cryptographic integrity verification, ensuring that every record is immutable from the moment of capture and that any subsequent modification leaves a detectable, attributable audit trail.

    • ALCOA+ compliance dashboard

      Compliance status visible to quality teams at a glance

      Deliver a real-time ALCOA+ compliance dashboard that monitors data completeness, timeliness, traceability and consistency across all decentralized SiPlex units, alerting quality teams to emerging compliance risks before they become audit findings.

    • ALCOA+ compliance demonstrable at every hospital site through system-enforced data integrity controls, not manual procedures.
    • GMP audit preparation transformed from retrospective evidence assembly to continuous compliance reporting.
    • Data integrity violations detected and remediated in real time, before they compound into batch failures or regulatory findings.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Zero-trust OT cybersecurity framework for distributed SiPlex units

    We implement a comprehensive Zero Trust security architecture for the SiPlex platform, covering device identity and authentication, network micro-segmentation, continuous monitoring, and IEC 62443 compliance documentation that protects patient genetic data and prevents production sabotage across all hospital-deployed units.

    • OT device identity and authentication layer

      Every device authenticated before it can communicate

      Deploy certificate-based device identity and mutual authentication for all SiPlex components and hospital network connections, ensuring that no device can communicate without verified credentials.

    • Network micro-segmentation and monitoring

      Production network isolated from hospital IT by design

      Implement network micro-segmentation that isolates the SiPlex OT network from hospital IT systems, with continuous monitoring that detects anomalous behaviour and lateral movement attempts without disrupting manufacturing operations.

    • IEC 62443 compliance pack

      Audit-ready evidence of security controls

      Produce a structured IEC 62443 and NIS2 compliance documentation pack — security requirements specifications, security-level verification evidence, incident response procedures — ready for regulatory submission without last-minute assembly.

    • Patient genetic data protected by zero-trust architecture that assumes breach and limits blast radius.
    • IEC 62443 and NIS2 compliance demonstrable to regulators through structured evidence rather than retrospective documentation.
    • Production integrity protected from cyberattacks that could alter cell processing parameters or compromise product quality.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Cloud-based fleet management platform for distributed SiPlex operations

    We build a cloud-based fleet management infrastructure for Sarcura's distributed SiPlex manufacturing units, enabling centralised remote monitoring, predictive maintenance, coordinated software deployment and operational analytics across all hospital-deployed devices from a single operations centre.

    • Centralised remote monitoring and alerting

      Every deployed unit visible from one operations centre

      Build a centralised monitoring platform that aggregates real-time health and performance data from all deployed SiPlex units, giving the operations team a live view of fleet-wide status and automated alerts when any unit approaches a threshold.

    • Predictive maintenance and firmware orchestration

      Updates deployed and maintenance scheduled before failures occur

      Implement predictive maintenance models trained on fleet-wide operational data, combined with coordinated firmware and software update orchestration that minimises disruption while keeping all units current.

    • Cross-site operational analytics

      Learning from every site to improve every site

      Develop fleet-wide operational analytics that identify performance trends, common failure modes and optimisation opportunities across all deployment sites, enabling product improvements informed by real-world operational data.

    • On-site engineer visits reduced by predictive maintenance that addresses issues before they require physical intervention.
    • Software update consistency across the fleet guaranteed by coordinated deployment from a single orchestration point.
    • Product roadmap informed by real-world operational data from all deployment sites, not just the most recently visited.

    We've done this before

    See how we do Digital CDMO

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Sarcura GmbH's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Process Automation 55 → 90
The SiPlex platform is progressing from proof-of-concept to commercial production. Operator-dependent manual workflows for cell processing remain in place, with real-time on-chip analytics in early deployment alongside imec.
Data Integration 45 → 85
Data from on-chip sensors, offline analytics and hospital records is not yet unified in a real-time platform. Manual data transfer and paper-based records at hospital deployment sites create integration gaps that ALCOA+ compliance audits flag.
Cybersecurity 40 → 90
Zero-trust OT security architecture is not yet deployed across the distributed device fleet. IEC 62443 and NIS2 compliance requirements have been identified as gaps but no structured remediation programme is in place.
Regulatory Compliance 50 → 95
GMP-compliant quality management infrastructure is in build-out. Electronic batch records, tamper-proof audit trails and ALCOA+ compliance automation are not yet production-ready for decentralized hospital deployment.
Remote Operations 35 → 80
Cloud-based fleet management infrastructure is not yet deployed. Software updates, performance monitoring and technical support for distributed hospital units rely on ad hoc processes rather than a centralised operations platform.
Interoperability 45 → 85
MTP-compliant modular architecture is not yet implemented. SiPlex integration with hospital laboratory infrastructure requires custom work at each site. OPC UA connectivity is in planning but not yet deployed.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Sarcura GmbH, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].